These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32327714)

  • 1. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.
    Zhang J; Liu S; Li Q; Shi Y; Wu Y; Liu F; Wang S; Zaky MY; Yousuf W; Sun Q; Guo D; Wang T; Zhang Y; Wang Y; Li M; Liu H
    Cell Death Differ; 2020 Sep; 27(9):2710-2725. PubMed ID: 32327714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells.
    Castagnola P; Bellese G; Birocchi F; Gagliani MC; Tacchetti C; Cortese K
    Oncotarget; 2016 Dec; 7(51):85411-85429. PubMed ID: 27863425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
    Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
    Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase C mediated internalization of ErbB2 is independent of clathrin, ubiquitination and Hsp90 dissociation.
    Dietrich M; Malik MS; Nikolaysen F; Skeie M; Stang E
    Exp Cell Res; 2018 Oct; 371(1):139-150. PubMed ID: 30098331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
    Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
    Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments.
    Cortese K; Howes MT; Lundmark R; Tagliatti E; Bagnato P; Petrelli A; Bono M; McMahon HT; Parton RG; Tacchetti C
    Mol Biol Cell; 2013 Jan; 24(2):129-44. PubMed ID: 23154999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
    Asp N; Pust S; Sandvig K
    Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.
    Raja SM; Clubb RJ; Bhattacharyya M; Dimri M; Cheng H; Pan W; Ortega-Cava C; Lakku-Reddi A; Naramura M; Band V; Band H
    Cancer Biol Ther; 2008 Oct; 7(10):1630-40. PubMed ID: 18769124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A kinase inhibitor screen reveals protein kinase C-dependent endocytic recycling of ErbB2 in breast cancer cells.
    Bailey TA; Luan H; Tom E; Bielecki TA; Mohapatra B; Ahmad G; George M; Kelly DL; Natarajan A; Raja SM; Band V; Band H
    J Biol Chem; 2014 Oct; 289(44):30443-30458. PubMed ID: 25225290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clathrin-independent endocytosis of ErbB2 in geldanamycin-treated human breast cancer cells.
    Barr DJ; Ostermeyer-Fay AG; Matundan RA; Brown DA
    J Cell Sci; 2008 Oct; 121(Pt 19):3155-66. PubMed ID: 18765569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination.
    Marx C; Held JM; Gibson BW; Benz CC
    Cancer Res; 2010 May; 70(9):3709-17. PubMed ID: 20406983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin.
    Austin CD; De Mazière AM; Pisacane PI; van Dijk SM; Eigenbrot C; Sliwkowski MX; Klumperman J; Scheller RH
    Mol Biol Cell; 2004 Dec; 15(12):5268-82. PubMed ID: 15385631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer.
    Zhang J; Li Q; Wu Y; Wang D; Xu L; Zhang Y; Wang S; Wang T; Liu F; Zaky MY; Hou S; Liu S; Zou K; Lei H; Zou L; Zhang Y; Liu H
    Cell Commun Signal; 2019 Feb; 17(1):15. PubMed ID: 30786890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.
    Schulz R; Marchenko ND; Holembowski L; Fingerle-Rowson G; Pesic M; Zender L; Dobbelstein M; Moll UM
    J Exp Med; 2012 Feb; 209(2):275-89. PubMed ID: 22271573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus.
    Lerdrup M; Bruun S; Grandal MV; Roepstorff K; Kristensen MM; Hommelgaard AM; van Deurs B
    Mol Biol Cell; 2007 Sep; 18(9):3656-66. PubMed ID: 17626164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubiquitination and downregulation of ErbB2 and estrogen receptor-alpha by kinase inhibitor MP-412 in human breast cancer cells.
    Suzuki T; Fujii A; Ochi H; Nakamura H
    J Cell Biochem; 2011 Sep; 112(9):2279-86. PubMed ID: 21503962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ErbB2 degradation mediated by the co-chaperone protein CHIP.
    Zhou P; Fernandes N; Dodge IL; Reddi AL; Rao N; Safran H; DiPetrillo TA; Wazer DE; Band V; Band H
    J Biol Chem; 2003 Apr; 278(16):13829-37. PubMed ID: 12574167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
    Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
    Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.